Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cervical cancer patterns with automation-assisted and conventional cytological screening: a randomized study.

Anttila A, Pokhrel A, Kotaniemi-Talonen L, Hakama M, Malila N, Nieminen P.

Int J Cancer. 2011 Mar 1;128(5):1204-12. doi: 10.1002/ijc.25677. Epub 2010 Nov 12.

2.

Randomized evaluation trial on automation-assisted screening for cervical cancer: results after 777,000 invitations.

Nieminen P, Kotaniemi-Talonen L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, Ikkala J, Anttila A.

J Med Screen. 2007;14(1):23-8.

PMID:
17362568
3.

A randomised public-health trial on automation-assisted screening for cervical cancer in Finland: performance with 470,000 invitations.

Nieminen P, Kotaniemi L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, Ikkala J, Luostarinen T, Anttila A.

Int J Cancer. 2005 Jun 10;115(2):307-11.

4.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
5.

[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].

Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Review. Italian.

6.

Alternative technologies in cervical cancer screening: a randomised evaluation trial.

Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P.

BMC Public Health. 2006 Oct 16;6:252.

7.

High-grade cervical abnormalities and screening intervals in New South Wales, Australia.

Schindeler S, Morrell S, Zuo Y, Baker D.

J Med Screen. 2008;15(1):36-43. doi: 10.1258/jms.2008.007036. Erratum in: J Med Screen. 2009;16(2):104-5.

PMID:
18416954
8.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group.

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

PMID:
16757701
9.
10.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
11.

[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].

Della Palma P, Moresco L, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43. Italian.

12.
13.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
14.

Risk of cervical cancer subsequent to a positive screening cytology: follow-up study in Finland.

Viikki M, Pukkala E, Hakama M.

Acta Obstet Gynecol Scand. 2000 Jul;79(7):576-9.

PMID:
10929958
15.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
16.

Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.

Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, Hogewoning CJ, Zaal A, Verheijen RH, Snijders PJ, Meijer CJ.

Lancet Oncol. 2011 May;12(5):441-50. doi: 10.1016/S1470-2045(11)70078-X.

PMID:
21530398
17.
18.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

19.

HPV testing with cytology triage for cervical cancer screening in routine practice.

Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A.

Am J Obstet Gynecol. 2014 May;210(5):474.e1-7. doi: 10.1016/j.ajog.2013.12.033. Epub 2013 Dec 25.

PMID:
24373948
20.

Risk of cervical cancer after a negative Pap smear.

Viikki M, Pukkala E, Hakama M.

J Med Screen. 1999;6(2):103-7.

PMID:
10444730

Supplemental Content

Support Center